- Conditions
- Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- duloxetine hydrochloride, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 475
- States / cities
- Antioch, California • Berkeley, California • Burlingame, California + 328 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1969–1992
of 7,461
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
- Interventions
- Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture, Magnetic Resonance Imaging, Radiation Therapy, Trametinib Dimethyl Sulfoxide
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 106 more
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
- Conditions
- NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
- Interventions
- Satralizumab, Placebo
- Drug · Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Newport Beach, California • San Francisco, California + 7 more
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Graft Versus Host Disease, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
- Interventions
- thiotepa, cyclophosphamide, tacrolimus, methotrexate, sirolimus, total body irradiation
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Duarte, California • Oakland, California + 40 more
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Disorders, Acute Lymphocytic Leukemia, Acute Promyelocytic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia
- Interventions
- Clofarabine, Cyclophosphamide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Gainesville, Florida + 3 more
- Conditions
- Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Cytarabine, Dexamethasone, Hydrocortisone Sodium Succinate, Lumbar Puncture, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Vincristine Sulfate
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 213
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 151 more
- Conditions
- Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 365 Days to 30 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more
- Conditions
- Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- OMP-54F28, Nab-Paclitaxel and Gemcitabine
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 2 more
- Conditions
- Epilepsy
- Interventions
- USL261
- Drug
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Fresno, California • Ventura, California + 13 more
- Conditions
- Dementia With Lewy Bodies
- Interventions
- CT1812
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
- Conditions
- HIV Infections
- Interventions
- Zidovudine, Zalcitabine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1993
- U.S. locations
- 40
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 23 more
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Risdiplam
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 2 Months and older
- U.S. locations
- 29
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more
- Conditions
- Graft-versus-host Disease (GVHD)
- Interventions
- Itacitinib, Placebo, Prednisone, Methylprednisolone
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 49
- States / cities
- La Jolla, California • Los Angeles, California • Stanford, California + 38 more
- Conditions
- Type 1 Diabetes
- Interventions
- Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature, Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
- Device
- Lead sponsor
- Medtronic MiniMed, Inc.
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Escondido, California • San Mateo, California + 14 more
- Conditions
- Rheumatoid Arthritis (RA), Hidradenitis Suppurativa (HS)
- Interventions
- Long Term Safety Monitoring Procedures
- Other
- Lead sponsor
- Sonoma Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 71 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2040
- U.S. locations
- 10
- States / cities
- San Francisco, California • Stanford, California • Aurora, Colorado + 5 more
- Conditions
- Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
- Interventions
- Envafolimab, Ipilimumab
- Biological · Drug
- Lead sponsor
- Tracon Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Los Angeles, California • Santa Monica, California + 22 more
- Conditions
- Multiple Sclerosis
- Interventions
- ONO-4641
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Aurora, Colorado • Fort Collins, Colorado + 17 more
- Conditions
- Amyloidosis
- Interventions
- Belantamab mafodotin, Cyclophosphamide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 5 more
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 2,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 480
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more
- Conditions
- Infertility, Female, Obesity
- Interventions
- Microdialysis, Vascepa - Fish Oil, Aspirin, Pioglitazone
- Other · Dietary Supplement · Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Scoliosis, Adolescent Idiopathic Scoliosis
- Interventions
- Maximum Number of Screws, Minimum Number of Screws
- Procedure
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Wilmington, Delaware • Washington D.C., District of Columbia + 10 more
- Conditions
- Charcot-Marie-Tooth Disease
- Interventions
- FLX-787-ODT (orally disintegrating tablet), Placebo ODT
- Drug
- Lead sponsor
- Flex Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • New Britain, Connecticut + 16 more
- Conditions
- Total Joint Arthroplasty
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2061
- U.S. locations
- 1
- States / cities
- Aurora, Colorado